Previous close | 0.4000 |
Open | 0.4000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 12.50 |
Expiry date | 2023-05-19 |
Day's range | 0.4000 - 0.4000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.
Liquidia Technologies, Inc. (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, presented preclinical data highlighting the Company’s next generation DaggerTM platform technology at the Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy Keystone Symposia in Banff, Alberta, Canada. The Dagger technology, first unveiled at the Company’